GLO1 and cystic fibrosis: We could also demonstrate that anakinra, the recombinant version of the interleukin-1 receptor antagonist, that has been shown to reduce inflammatory pathology in murine and human CF [10,11,12], was able to rescue GLO1 in CF, thus indicating that GLO1 represents a potential target to dampen inflammation in CF.